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tory blood pressure monitoring data to echocardiographic findingsTo the Editor: I read with great interest the recent in haemodialysis patients. Nephrol Dial Transplant 11:2050–2054,
article that appeared in Kidney International by Foley 1996
3. Conlon PJ, Walshe JJ, Heinle SK, Minda S, Krucoff M, Schwaband co-workers [1]. Their study is quite novel because of
SJ: Predialysis systolic blood pressure correlates strongly with meanthe number of echocardiograms performed in sequence 24-hour systolic blood pressure and left ventricular mass in stable
during a relatively long period of follow-up. However, hemodialysis patients. J Am Soc Nephrol 7:2658–2663, 1996
4. Cannella G, Paoletti E, Delfino R, Peloso G, Rolla D, Moli-I would like to make a few comments on the study:
nari S: Prolonged therapy with ACE inhibitors induces a regressionFirst, blood pressure was defined as the average of all
of left ventricular hypertrophy of dialyzed uremic patients indepen-
measurements done. It might have been more appro- dently from hypotensive effects. Am J Kidney Dis 30:659–664, 1997
5. Pascual J, Teruel JL, Moya JL, Liano F, Jimenez-Mena M, Or-priate to analyze pre- and post-dialysis blood pressure
tuno J: Regression of left ventricular hypertrophy after partial cor-levels separately, since left ventricular mass (LVM) in-
rection of anemia with erythropoietin in patients on hemodialysis:
dex has been shown previously to correlate better with a prospective study. Clin Nephrol 35:280–287, 1991
pre-dialysis systolic blood pressure level [2, 3].
Second, it is not clear whether the patients’ antihyper-
To the Editor: The question of whether cardiac func-tensive medications were modified during the study pe-
tion improves or worsens after initiation of dialysis ther-riod. If angiotensin-converting enzyme inhibitors were
apy is still open. The paper by Foley et al [1] is a stepstarted after the first year, this would explain, at least in
forward towards resolving this issue. The authors con-some patients, why further significant LVM enlargement
cluded that left ventricular dilation with compensatorydid not develop [4].
hypertrophy continued after the start of dialysis therapy,Finally, I do not share the authors’ conclusion that
particularly in the first year of therapy. A few relevantintervention beyond the first year of dialysis treatment
papers concerning this problem were published earlier,might be relatively ineffective to prevent progressive
but the Authors did not cite them [2, 3].cardiac enlargement. In contrast, I think that the rela-
The study by Foley et al was prospective. The patienttively normal blood pressure levels and desirable hemo-
subset was highly selected: only 29 of 433 patients whoglobin levels achieved prevented progression beyond one
started the study were analyzed. The patient subset wasyear. Indeed, previous studies demonstrated a significant
older than the parent population—58 vs. 51 years. Ageregression in LVM index after partial correction of ane-
is one of the major risk factors for the development ofmia with erythropoietin [5]. The problem remaining to
congestive heart failure in dialysis patients. The preva-be solved is why a significant cardiac enlargement devel-
lence of congestive heart failure was 21% at the startoped during the first year of the study, in spite of blood
of the study. The number of patients who developedpressure and hemoglobin levels comparable with those
congestive heart failure during the 41-month follow-upof the later periods.
is not given. Because cardiovascular response differsIn conclusion, much effort should be made to prevent
among hemodialysis (HD) patients and peritoneal dial-currently known risk factors from developing during the
ysis patients [4], we believe that echocardiographic find-entire course of the dialysis therapy, though further stud-
ings in these two groups should be analyzed separately.ies are needed to find out the exact mechanisms responsi-
It is very likely that hyperparathyroidism contributesble for the progressive cardiac enlargement.
to left ventricular hypertrophy (LVH) in dialysis patients
Sehsuvar Ertu¨rk and affects cardiac function [4, 5]. There are no data inDepartment of Nephrology,
the paper on PTH or alkaline phosphatase; in our opin-Ankara University School of Medicine,
Ibn-i Sina Hospital, ion, normal plasma calcium and phosphate concentra-
Ankara, Turkey tions do not exclude hyperparathyroidism. If the authors
look at the risk factors for the progression of cardiomeg-
aly in dialysis patients, the parameters describing para-
thyroid function must be taken into account. Because
parathyroid function fluctuates as dialysis is continued
and PTH concentration varies irrespective of the dura- 1999 by the International Society of Nephrology
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tion of renal replacement therapy, cardiac performance tory hypertrophy is the major long-time evolutionary
pattern” and that “intervention beyond one year maymay change as a function of PTH level but not as the
be relatively ineffective.”effect of duration of therapy. Such a possibility is sug-
The fact that better results were obtained with perito-gested by the data presented in Table 3. Results given
neal dialysis may simply be due to better volume controlin the second and third columns show that cardiac mass,
in those patients. Other studies [2] have shown that thisvolume and function indexes deteriorate in some pa-
is not always the case. The absence of a relationship withtients but improve or do not change in others. The differ-
blood pressure could be related to the confounding effectences may depend on mode of dialysis and PTH concen-
of antihypertensive drugs, but probably also to an inde-tration.
pendent effect of volume retention.Therapy with EPO leads to the regression of LVH in
We recently showed [3] that prolonged strict volumedialysis patients. The mean hemoglobin level in the study
control can cause regression of dilatation and hypertro-group presented in the first column of Table 4 is 8.6 g/dl
phy of the left ventricle while abolishing the need for(range, 8.1–9.2), but the data plotted in Figure 1 reveal
antihypertensive drugs. An extreme example of a patientthat as many as 9 HD patients had a hemoglobin level
in whom volume control caused complete regression ofbelow 8 g/dl. We are curious as to whether these patients,
severe cardiomyopathy without hypertension [4] illus-particularly those with hemoglobin levels of 6–7 g/dl,
trates the importance of hypervolemia as an independentwere given EPO. If yes, it should be mentioned, because
risk factor. Clearly (as Foley et al stressed in earlierthis hormone affects cardiac function regardless of renal
publications) only intervention studies can definitely re-replacement therapy. If EPO was not given to these
solve the complicated problems of dialysis morbidity.patients, one wonders why the authors did not address
the severe anemia. Hu¨seyin To¨z, Mehmet O¨zkahya,
Evert J. Dorhout Mees
Paweł Stro´z˙ecki, Gwidon Polak, Ege University Medical School, Nephrology Department,
Małgorzata Ukleja-Adamowicz, Boz˙ena Pa¸czkowska, Bornova, Izmir, Tu¨rkiye
Graz˙yna Zarzycka-Lindner, Wirginia Tomczak-Watras,
Andrzej Adamowicz, and Jacek Manitius Correspondence to: Hu¨seyin To¨z, M.D., Ege University Medical
Department of Nephrology, School, Nephrology Department, Bornova, 35100 Izmir, Tu¨rkiye
The Ludwik Rydygier Medical University, Bydgoszcz, Poland
REFERENCES
REFERENCES
1. Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre
PE: Long-term evolution of cardiomyopathy in dialysis patients.1. Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre
Kidney Int 54:1720–1725, 1998PE: Long-term evolution of cardiomyopathy in dialysis patients.
2. Lameire N, Vanholder RC, Van Loo A, Lambert MC, Vijt D, VanKidney Int 54:1720–1725, 1998
Bockstaele, Vogeleere P, Ringoir SM: Cardiovascular diseases in2. Cohen JL, Barooah B, Segal KR, Batuman V: Two-dimensional
peritoneal dialysis patients: the size of the problem. Kidney Intechocardiographic findings in patients on hemodialysis for more
Suppl 56:S28–S36, 1996than six months. Am J Cardiol 60:743–745, 1987
3. O¨zkahya M, Ok E, Cirit M, Aydin S¸, Akc¸ic¸ek F, Bas¸c¸i A, Dorhout3. Leenen FH, Smith DL, Khanna R, Oreopoulos DG: Changes in
Mees EJ: Regression of left ventricular hypertrophy in haemodial-left ventricular hypertrophy and function in hypertensive patients on
ysis patients by ultrafiltration and reduced salt intake without antihy-continuous ambulatory peritoneal dialysis. Am Heart J 110:102–106,
pertensive drugs. Nephrol Dial Transplant 13:1489–1493, 19981985
4. To¨z H, O¨zerkan F, U¨nsal A, Soyda C, Dorhout Mees EJ: Dilated4. Harnett JD, Parfrey PS, Griffiths SM, Gault MH, Barre P,
uremic cardiomyopathy in a dialysis patient cured by persistentGuttmann RD: Left ventricular hypertrophy in end-stage renal
ultrafiltration. Am J Kidney Dis 32:664–668, 1998disease. Nephron 48:107–115, 1988
5. Hara S, Ubara Y, Arizono K, Ikeguchi H, Katori H, Yamada
A, Ogura Y, Murata H, Mimura N: Relation between parathyroid
hormone and cardiac function in long-term hemodialysis patients. Reply from the authors
Miner Electrolyte Matab 21:72–76, 1995
To the Editor: We would like to thank all the corre-
spondents for their interest and helpful queries and com-
To the Editor: We would like to comment on the study ments.
of Foley et al [1]. In our opinion it is not correct to speak Dr. Erturk makes several reasonable points. It cer-
about the “natural history of cardiomyopathy” because tainly would have been of interest to look at the potential
the development of this cardiomyopathy is highly depen- role of post-dialysis blood pressures in the hemodialysis
dent on the way patients are treated, particularly the patients. The short answer is that we did not record
extent to which the treating team succeeds in controlling them, partly reflecting the fact that the study began in
“volume.” the early 1980s. It is hardly fair to say that post-dialysis
The fatalistic attitude that unfortunately prevails in blood pressure is a better predictor of LV mass index
many dialysis centres is supported by the conclusion that than pre-dialysis blood pressure. We have previously
shown, in a prospective cohort study of over a thousand“progressive left ventricular dilatation with compensa-
